Peptide

Cartalax

Also known as

AED peptide · Ala-Glu-Asp · Alanyl-glutamyl-aspartic acid · T-31 · AC-4 · AC4 · cartilage bioregulator · Cartalax Cytogen · Khavinson cartilage peptide · cartilage and bone tissue bioregulator

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Joint-focused bioregulator	Cartalax is the synthetic three-amino-acid peptide AED, discussed for worn or painful joints and easier movement.
Different product forms	Oral capsules, sublingual drops and injected AED powder are different products. Tissue-extract mixtures such as Sigumir are not equivalent to pure AED.

Notes

Cartalax is a synthetic three-amino-acid peptide, AED, discussed for worn or painful joints and easier movement. People hope it can influence cartilage maintenance. Reports range from striking hip or knee relief to no change after months; feeling better does not demonstrate new cartilage.

AED means alanine–glutamic acid–aspartic acid. It belongs to the Russian Khavinson bioregulator family. The proposed idea is a small signal affecting cell activity, rather than a supply of cartilage-building material. Cartilage is the smooth tissue covering bone ends; a cartilage-related claim is not proof that a peptide reaches or rebuilds it. RU2299741C1: Ala-Glu-Asp peptide patent (Official context · Accessed 2026-09-30)

Capsules, drops and injected powder are different products. The existing discussion includes oral Cartalax Cytogen/AC-4, sublingual drops and research AED powder. Cytomax tissue-extract products such as Sigumir contain peptide mixtures. Similar marketing does not make those products interchangeable, and capsule weight is not necessarily the amount of AED.

Source context — RU2299741C1: Ala-Glu-Asp peptide patent: Machine-translated applicant patent, not independent clinical verification. Twenty-nine patients; control group mentioned but comparative results/statistics inadequately reported. No major X-ray changes claimed. Formal IM amounts are excluded from the community quick subjects. Animal explant findings not represented as human cartilage regrowth.

What people notice

Less ache and stiffness	One hip-arthritis user described substantial relief; older accounts mention easier warm-ups and less morning stiffness. These reports do not demonstrate new cartilage.
No change also appears	Reports include difficulty judging 1 mg daily, months at 2 mg daily without benefit and an unchanged knee diary after eight weeks of capsules.

Notes

Less joint ache and easier movement. A SubQ user with a previous hip replacement described substantial relief in the other hip, but supplied no dose or timing. Older accounts emphasize less morning stiffness and easier warm-ups. These are comfort and function reports, not evidence of avoiding surgery or reversing arthritis. Cartalax experience/dosage? (Personal report · Accessed 2026-09-30)

Training tolerance can improve—or stay unchanged. One heavily stacked lifter reported easier movement; another poster found 1 mg daily hard to judge. A separate discussion includes months at 2 mg daily without benefit. Neither a success nor a null result establishes what a different joint problem will do. Cartalax experience? Added to KLOW stack? ACL, LCL, meniscus (Personal report · Accessed 2026-09-30) · Has anybody heard of Cartalax or the Deadpool Blend? (Community discussion · Accessed 2026-09-30)

No improvement appears even in serious recovery attempts. The ACL poster later reported no discernible effect after two months, while acknowledging surgery confounded judgment. Another account describes no hip improvement before replacement despite several other peptides and exercise. A ResearchSafe capsule user reports an unchanged knee-discomfort diary after eight weeks; the page has truncated replies and unverified authorship. Cartalax experience/dosage? (Personal report · Accessed 2026-09-30) · Cartalax people, help me out!! (Community discussion · Accessed 2026-09-30) · Anyone actually gotten real results from Cartalax? (Personal report · Accessed 2026-09-30)

Source context — Cartalax experience/dosage?: Self-reports; positive hip account lacks dose/timing. Null account literally says '2mh', an unresolved unit typo, so its amount is not silently corrected. ACL surgery and recovery stacks confound follow-up; hidden replies not inspected.

Source context — Cartalax experience? Added to KLOW stack? ACL, LCL, meniscus: Anecdotal benefit amid growth hormone, steroids, KLOW and collagen. 10 mg and 5 mg account routes not explicitly stated. Uncertain 1 mg response is distinct from a planned dose. Promotional community infrastructure and hidden replies limit independence.

Source context — Has anybody heard of Cartalax or the Deadpool Blend?: Product and route uncertain; blend ratios not supplied. Weight-based escalation is explicitly vague secondhand information, not verified guidance. Cartilage-regrowth goal is not an observed endpoint; TikTok testimony is secondhand and not inspected.

Source context — Cartalax people, help me out!!: Batch suspicion untested; no dose or route for hip null report; heavily stacked. NF-kB assertions and counterclaims are opinions, not demonstrated human adverse events. Linked PMC body blocked; no independent validation of the mechanistic dispute.

Source context — Anyone actually gotten real results from Cartalax?: No visible original dates, author verification or capsule content/amount. Replies cut off mid-sentence. Website-hosted accounts cannot be independently authenticated; forum absorption opinions are not PK evidence. Limited use as a displayed report only.

Doses people talk about

2 mg SubQ account	A shoulder-recovery log records 2 mg Cartalax daily with BPC-157 500 mcg and TB-500 500 mcg daily. At day two, the planned 20-day course had no outcome yet.
Higher reported totals	Separate, heavily stacked accounts describe 10 mg daily or 5 mg twice daily for 20 days. Another lists 5 mg on 5–7 days weekly for 20 days, route unstated.
Competing lower charts	Older SubQ charts list 100–250 mcg, 0.2–2 mg or 1–2 mg daily. These conflicting bands are not equivalent units or an escalation ladder.
Oral product calendar	Two capsules daily for about 30 days appears in oral guides. Capsule weight and assumed absorption do not establish an injectable AED equivalent.

Notes

SubQ: 2 mg daily in an opened recovery log. The shoulder-surgery poster combined it with daily BPC-157/TB-500 totaling 1 mg: 500 mcg of each. Their intended Cartalax course was 20 days. The post was only at day 2, so it records use rather than an outcome. Cartalax & BPC-157/TB-500 Blend Stack (Personal report · Accessed 2026-09-30)

Higher reports: 10 mg daily, or 5 mg twice daily. Separate posters describe 20-day courses at those totals; both used substantial other stacks. Another reports 5 mg on 5–7 days per week for 20 days, with route unstated. These are individual practices, not an established dose-response relationship. Cartalax experience? Added to KLOW stack? ACL, LCL, meniscus (Personal report · Accessed 2026-09-30) · Cartalax & BPC-157/TB-500 Blend Stack (Personal report · Accessed 2026-09-30)

Older SubQ charts disagree: 100–250 mcg, 0.2–2 mg, or 1–2 mg daily. These preserved chart bands have unrecovered original links. The same record includes 10 mg daily for 10 days and 5 mg twice daily for 10–20 days. Keep the competing conventions separate: 10 mg is 40–100 times the 100–250 mcg band, not a unit conversion.

Oral product talk: 2 capsules daily for about 30 days. Older guides describe later 10-day pulses. Separate oral/sublingual estimates of 15–20 mg versus 10 mg injected rely on assumed absorption. The quoted oral 30–50%, sublingual 40–60% and SubQ 80–90% figures remain unverified guesses, not conversion factors.

Source context — Cartalax & BPC-157/TB-500 Blend Stack: OP records day 2 and proposed schedule, not completed results. Positive responder uses a heavy multi-compound stack; their Cartalax route not explicitly confirmed. No verified surgery cancellation or tissue endpoint.

Half-life, onset & duration

Felt onset	One 10 mg/day user reported joint improvement by day three while using several other compounds. Other claims span days to weeks.
Felt duration	Single-dose duration and a dependable after-stopping benefit window are unknown. Older claims of 2–8 weeks or months after a course are not established by the opened accounts.
Half-life	No dependable human AED half-life is established here. Seconds-to-minutes estimates and a 30-minute claim remain unverified.

Notes

Day 3 in one stacked report; no typical onset follows. The 10 mg/day lifter reported major joint improvement by day 3 and training records within a week, while also using growth hormone, a steroid, KLOW and collagen. The other reports do not supply a comparable time-to-benefit. Cartalax experience? Added to KLOW stack? ACL, LCL, meniscus (Personal report · Accessed 2026-09-30)

Slower timelines are circulated claims, not measured milestones. Older notes discuss subtle change at days 4–10 or the end of a 10–20-day block, and oral reassessment over 4–12 weeks. A seller's social guide instead lists possible comfort changes at weeks 2–3. None supports promising an onset; no change remains possible. ParamountPeptide Cartalax injectable guide (commercial social post) (Secondhand community claim · Accessed 2026-09-30)

Single-dose duration and lasting benefit are unknown. Older bioregulator talk claims residual changes for 2–8 weeks, sometimes months after a course. The opened accounts do not establish a reliable after-stopping window. Thirty days of dosing, two months of follow-up and a proposed quarterly repeat are different measures, not the duration of one dose. Cartalax experience/dosage? (Personal report · Accessed 2026-09-30)

No dependable human Cartalax half-life is established here. Earlier discussion includes seconds-to-minutes estimates and an unverified 30-minute claim; neither is a measured AED value. Half-life describes the amount falling by half, not how long a joint feels better or when to repeat a course.

Source context — ParamountPeptide Cartalax injectable guide (commercial social post): Seller-linked promotional guide, not a first-person log or validated human protocol. Claims of 'common' use not counted as consensus. Only its circulated amounts/timing are described, with commercial origin explicit.

Cycles people discuss

Injection calendars	10–20-day blocks, month-long courses and continuous use coexist. Accounts include 20 on/10 off plans and a 30-on/30-off/30-on course without benefit.
Oral and repeat calendars	Oral guides describe 30 days then 10-day pulses, often every three months. Other charts use different breaks; none settles a safe or effective repeat interval.

Notes

10–20-day blocks compete with month-long or continuous use. Old injectable calendars repeat every 3–6 months; some shorten that to 2–3 months. Opened accounts include a planned 20-on/10-off schedule, 20 days repeated 1–2 times yearly, and 30-on/30-off/30-on with no benefit. Continuous use appears too; no comparison settles the best pattern. Cartalax & BPC-157/TB-500 Blend Stack (Personal report · Accessed 2026-09-30) · Cartalax experience? Added to KLOW stack? ACL, LCL, meniscus (Personal report · Accessed 2026-09-30) · Cartalax experience/dosage? (Personal report · Accessed 2026-09-30)

Oral calendars and promotional calendars differ. Preserved oral guides describe a 30-day intensive, then 10-day pulses every 3 months, or every 1–2 months in stronger marketing claims. The seller's injectable guide lists 20–30 days with 1–2 months off. The short-course 'signal then stop' rationale is bioregulator theory, not proof of safety or persistence. ParamountPeptide Cartalax injectable guide (commercial social post) (Secondhand community claim · Accessed 2026-09-30)

Stacks

BPC-157 and TB-500	The Cartalax/BPC-157/TB-500 trio is called Deadpool in some discussion. Reports describe joint or running benefits, without dependable component amounts in those blend stories.
Other repair and joint layers	GHK-Cu, KPV, collagen and joint supplements recur. One positive account also used Vesugen and Pinealon; the mix prevents identifying which ingredient helped.

Notes

Stack success cannot identify the useful ingredient. A poster reporting disappearance of arthritis pain also used Vesugen, Pinealon, BPC, TB and collagen. 'Deadpool' discussion means Cartalax/BPC-157/TB-500, with knee-running benefits claimed but no reliable component amounts supplied. Other old stacks add GHK-Cu, KPV, Epitalon or joint supplements; the mix is a major confounder. Cartalax & BPC-157/TB-500 Blend Stack (Personal report · Accessed 2026-09-30) · Has anybody heard of Cartalax or the Deadpool Blend? (Community discussion · Accessed 2026-09-30)

Wolverine-adjacent triple: Cartalax + BPC-157 + TB-500/TB4 for mobility + multi-tissue recovery; Cartalax stays the short cyclic piece. [community]

Collagen peptides / bone broth: Continuous collagen (community often ~10–20 g/day) as “building blocks” while Cartalax is the cyclic signal — confounded nutrition stack. [community]

Micronutrient joint stack: Vitamin C, manganese, glucosamine/chondroitin, omega-3s appear in lifestyle sidebars next to Cartalax protocols. [community]

Watch for

Unwanted reactions	The retained reports include injection redness, itching, swelling, nausea, headache, dizziness and fatigue. Their frequency is unknown, and many involve stacks.
Pain relief versus repair	Less pain or an easier workout does not confirm cartilage regrowth. Physical therapy, deloads and weight changes can also alter symptoms.
Identity and signaling concerns	Same-vial compatibility and product contents remain uncertain. Cancer and inflammation arguments are unresolved; short courses do not establish long-term safety.

Notes

Reactions are reported; their frequency is unknown. The preserved community record includes redness, itching, stinging or swelling at injection sites, nausea at higher totals, headache, lightheadedness, fatigue and blood-pressure caution talk. These reports lack individual source links and often involve stacks. They cannot establish a side-effect rate or make 'minimal sides' marketing a safety finding.

Less pain does not confirm cartilage repair. A returning ache, a comfortable workout or a positive testimonial cannot show whether cartilage regrew. Old accounts also mention PT, deloads and weight management. Those changes can affect joint symptoms and make attributing an improvement to Cartalax difficult. Cartalax experience/dosage? (Personal report · Accessed 2026-09-30)

Route arguments and product doubts do not settle the outcome. An opened poster suspected an ineffective batch was glucose, without presenting a test. Older discussion debates systemic dosing versus near-injury injections and rare joint-injection marketing. There is no demonstrated route advantage here. Same-vial combinations also have unresolved compatibility; appearance alone cannot verify identity, purity or sterility. Cartalax people, help me out!! (Community discussion · Accessed 2026-09-30)

Growth-signaling worries remain unresolved. Community discussion raises cancer and inflammation concerns, with disagreement about what cell findings mean. Neither forum reassurance nor mechanistic speculation demonstrates human harm or safety. Pregnancy, breastfeeding and long-term high-dose use remain evidence gaps; short courses do not remove product-quality or injection risks. Cartalax people, help me out!! (Community discussion · Accessed 2026-09-30)

Full notes

What Cartalax is

AED means alanine–glutamic acid–aspartic acid. It belongs to the Russian Khavinson bioregulator family. The proposed idea is a small signal affecting cell activity, rather than a supply of cartilage-building material. Cartilage is the smooth tissue covering bone ends; a cartilage-related claim is not proof that a peptide reaches or rebuilds it. Official context Community
Capsules, drops and injected powder are different products. The existing discussion includes oral Cartalax Cytogen/AC-4, sublingual drops and research AED powder. Cytomax tissue-extract products such as Sigumir contain peptide mixtures. Similar marketing does not make those products interchangeable, and capsule weight is not necessarily the amount of AED. Community

What people hope to notice

Less joint ache and easier movement. A SubQ user with a previous hip replacement described substantial relief in the other hip, but supplied no dose or timing. Older accounts emphasize less morning stiffness and easier warm-ups. These are comfort and function reports, not evidence of avoiding surgery or reversing arthritis. Personal report Community
Training tolerance can improve—or stay unchanged. One heavily stacked lifter reported easier movement; another poster found 1 mg daily hard to judge. A separate discussion includes months at 2 mg daily without benefit. Neither a success nor a null result establishes what a different joint problem will do. Personal report Reddit / r/Biohacking

Doses people discuss

Reported amounts and chart claims, not instructions. SubQ means beneath the skin; 1,000 micrograms (mcg) equals 1 milligram (mg).

SubQ: 2 mg daily in an opened recovery log. The shoulder-surgery poster combined it with daily BPC-157/TB-500 totaling 1 mg: 500 mcg of each. Their intended Cartalax course was 20 days. The post was only at day 2, so it records use rather than an outcome. Personal report
Higher reports: 10 mg daily, or 5 mg twice daily. Separate posters describe 20-day courses at those totals; both used substantial other stacks. Another reports 5 mg on 5–7 days per week for 20 days, with route unstated. These are individual practices, not an established dose-response relationship. Personal report Personal report
Older SubQ charts disagree: 100–250 mcg, 0.2–2 mg, or 1–2 mg daily. These preserved chart bands have unrecovered original links. The same record includes 10 mg daily for 10 days and 5 mg twice daily for 10–20 days. Keep the competing conventions separate: 10 mg is 40–100 times the 100–250 mcg band, not a unit conversion. Community
A commercial social guide lists 10–20 mcg/kg per day. Its injectable chart gives 700–1,400 mcg daily for 70 kg, once each morning. The post links a seller and discount code; it does not supply a measured human dose standard. Reddit / r/ParamountPeptide
Oral product talk: 2 capsules daily for about 30 days. Older guides describe later 10-day pulses. Separate oral/sublingual estimates of 15–20 mg versus 10 mg injected rely on assumed absorption. The quoted oral 30–50%, sublingual 40–60% and SubQ 80–90% figures remain unverified guesses, not conversion factors. Community

Half-life

No dependable human Cartalax half-life is established here. Earlier discussion includes seconds-to-minutes estimates and an unverified 30-minute claim; neither is a measured AED value. Half-life describes the amount falling by half, not how long a joint feels better or when to repeat a course. Community

Onset: when a change is noticed

Day 3 in one stacked report; no typical onset follows. The 10 mg/day lifter reported major joint improvement by day 3 and training records within a week, while also using growth hormone, a steroid, KLOW and collagen. The other reports do not supply a comparable time-to-benefit. Personal report
Slower timelines are circulated claims, not measured milestones. Older notes discuss subtle change at days 4–10 or the end of a 10–20-day block, and oral reassessment over 4–12 weeks. A seller's social guide instead lists possible comfort changes at weeks 2–3. None supports promising an onset; no change remains possible. Community Reddit / r/ParamountPeptide

Duration: how long a change lasts

Single-dose duration and lasting benefit are unknown. Older bioregulator talk claims residual changes for 2–8 weeks, sometimes months after a course. The opened accounts do not establish a reliable after-stopping window. Thirty days of dosing, two months of follow-up and a proposed quarterly repeat are different measures, not the duration of one dose. Community Personal report

Cycles and time off

10–20-day blocks compete with month-long or continuous use. Old injectable calendars repeat every 3–6 months; some shorten that to 2–3 months. Opened accounts include a planned 20-on/10-off schedule, 20 days repeated 1–2 times yearly, and 30-on/30-off/30-on with no benefit. Continuous use appears too; no comparison settles the best pattern. Community Personal report Personal report Personal report
Oral calendars and promotional calendars differ. Preserved oral guides describe a 30-day intensive, then 10-day pulses every 3 months, or every 1–2 months in stronger marketing claims. The seller's injectable guide lists 20–30 days with 1–2 months off. The short-course 'signal then stop' rationale is bioregulator theory, not proof of safety or persistence. Community Reddit / r/ParamountPeptide

Good to know

Reactions are reported; their frequency is unknown. The preserved community record includes redness, itching, stinging or swelling at injection sites, nausea at higher totals, headache, lightheadedness, fatigue and blood-pressure caution talk. These reports lack individual source links and often involve stacks. They cannot establish a side-effect rate or make 'minimal sides' marketing a safety finding. Community
Growth-signaling worries remain unresolved. Community discussion raises cancer and inflammation concerns, with disagreement about what cell findings mean. Neither forum reassurance nor mechanistic speculation demonstrates human harm or safety. Pregnancy, breastfeeding and long-term high-dose use remain evidence gaps; short courses do not remove product-quality or injection risks. Community Reddit / r/BodyHackGuide
Less pain does not confirm cartilage repair. A returning ache, a comfortable workout or a positive testimonial cannot show whether cartilage regrew. Old accounts also mention PT, deloads and weight management. Those changes can affect joint symptoms and make attributing an improvement to Cartalax difficult. Community Personal report

What the community accounts add

No improvement appears even in serious recovery attempts. The ACL poster later reported no discernible effect after two months, while acknowledging surgery confounded judgment. Another account describes no hip improvement before replacement despite several other peptides and exercise. A ResearchSafe capsule user reports an unchanged knee-discomfort diary after eight weeks; the page has truncated replies and unverified authorship. Personal report Reddit / r/BodyHackGuide Personal report
Stack success cannot identify the useful ingredient. A poster reporting disappearance of arthritis pain also used Vesugen, Pinealon, BPC, TB and collagen. 'Deadpool' discussion means Cartalax/BPC-157/TB-500, with knee-running benefits claimed but no reliable component amounts supplied. Other old stacks add GHK-Cu, KPV, Epitalon or joint supplements; the mix is a major confounder. Personal report Reddit / r/Biohacking Community
Higher-dose advice can become an expensive explanation for failure. One months-long nonresponder cited body-weight dosing secondhand and worried about using a vial daily. Replies asked for the source. The claim was not substantiated; nonresponse does not prove underdosing. Older 10 mg × 10-day calendars total 100 mg, versus 10–40 mg for 1–2 mg × 10–20 days. Reddit / r/Biohacking Community
Route arguments and product doubts do not settle the outcome. An opened poster suspected an ineffective batch was glucose, without presenting a test. Older discussion debates systemic dosing versus near-injury injections and rare joint-injection marketing. There is no demonstrated route advantage here. Same-vial combinations also have unresolved compatibility; appearance alone cannot verify identity, purity or sterility. Reddit / r/BodyHackGuide Community Community

What the formal source actually says

A patent describes human use, without establishing today's products. Example 5 reports 29 knee-osteoarthritis patients, intramuscular daily treatment for 20 days and age-dependent amounts of 1 mcg, 10 mcg or 5 mg. It claims symptom improvement but no significant X-ray change. Control outcomes are not presented sufficiently to establish comparative effectiveness. These are patent claims, not community dose ranges or proof of regrowth. Official context